Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
23 May 2023
Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC
In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.
Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC
21 May 2023
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.
Rituximab-temozolomide-radiation combo shows promise in recurrent primary CNS lymphoma
15 May 2023
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
